---
title: "Preconception, Gestational, and Postpartum Care for Type 2 Diabetes"
id: "endocrine-news-0-preconception-gestational-and-postpartum-care"
canonical_url: "https://medichelpline.com/clinical-feed/endocrine-news-0-preconception-gestational-and-postpartum-care"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "Endocrine News"
source_url: "https://endocrinenews.endocrine.org/preconception-gestational-and-postpartum-care/"
published_at: "2026-11-11T13:55:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Preconception, Gestational, and Postpartum Care for Type 2 Diabetes
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/endocrine-news-0-preconception-gestational-and-postpartum-care
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** Endocrine News
- **Source URL:** [Original Journal Publication](https://endocrinenews.endocrine.org/preconception-gestational-and-postpartum-care/)
- **Published At:** 2026-11-11T13:55:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Aoife M. Egan presented at **ENDO 2026** on coordinated care across preconception, pregnancy, and postpartum for people with **type 2 diabetes**. - The report summarizes clinical recommendations rather than original trial results; it is based on a Meet the Professor session and existing guidelines. - Key preconception steps include routine screening for pregnancy intent, medication review, counseling on nutrition and lifestyle, and screening for diabetes complications and infectious diseases. - During pregnancy the emphasis shifts to maintaining glycemic targets, supporting healthy weight through diet and exercise, and close monitoring for maternal and fetal complications. - Postpartum priorities include timely follow-up, documented transition plans in electronic medical records, designated care navigators for patients at high risk of loss to follow-up, and expanded use of virtual care. - Egan identified three principal practice gaps: lack of routine preconception counseling, uncertainty and rapid medication changes when pregnancy occurs on newer agents, and fragmentation of care across specialties and settings. - The presenter referenced the Endocrine Society/European Society guideline on preexisting diabetes and pregnancy for clinicians seeking specific medication and management guidance. - The article notes rising prevalence of pregestational diabetes, attribution to obesity and lifestyle trends, and disproportionate impact on underserved populations with barriers to access. - Evidence gaps remain regarding safety of newer glucose-lowering agents in pregnancy and optimal systems-based strategies to ensure seamless postpartum follow-up; the source article did not provide new trial data or precise implementation metrics.
## Clinical Analysis & Structured Key Points
[Skip to content](https://endocrinenews.endocrine.org/preconception-gestational-and-postpartum-care/#wp--skip-link--target) [Endocrine News](https://endocrinenews.endocrine.org) [![Endocrine News](https://endocrinenews.endocrine.org/wp-content/uploads/es-reversed.svg)](https://endocrinenews.endocrine.org/) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) * [Topics](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Diabetes](https://endocrinenews.endocrine.org/category/health-topic/diabetes/) * [Obesity](https://endocrinenews.endocrine.org/category/health-topic/obesity/) * [Adrenal](https://endocrinenews.endocrine.org/category/health-topic/adrenal/) * [Bone and Mineral](https://endocrinenews.endocrine.org/category/health-topic/bone-and-mineral/) * [Cardiometabolic](https://endocrinenews.endocrine.org/category/health-topic/cardiometabolic/) * [Endocrine Disruptors](https://endocrinenews.endocrine.org/category/health-topic/endocrine-disruptors/) * [Head Glands](https://endocrinenews.endocrine.org/category/health-topic/head-glands/) * [Kidney Issues](https://endocrinenews.endocrine.org/category/health-topic/kidney-issues/) * [Neoplasia and Cancer](https://endocrinenews.endocrine.org/category/health-topic/neoplasia-and-cancer/) * [Pancreas](https://endocrinenews.endocrine.org/category/health-topic/pancreas/) * [Reproductive Issues](https://endocrinenews.endocrine.org/category/health-topic/reproductive-issues/) * [Thyroid](https://endocrinenews.endocrine.org/category/health-topic/thyroid/) * [Pediatric Health](https://endocrinenews.endocrine.org/category/patient-populations/pediatric-health/) * [Men’s Health](https://endocrinenews.endocrine.org/category/patient-populations/mens-health/) * [Women’s Health](https://endocrinenews.endocrine.org/category/patient-populations/womens-health/) * [Why Endocrinology?](https://endocrinenews.endocrine.org/category/why-endocrinology/) * [Practice](https://endocrinenews.endocrine.org/category/practice/) * [Your Practice](https://endocrinenews.endocrine.org/category/practice/your-practice/) * [Your Patients](https://endocrinenews.endocrine.org/category/practice/your-patients/) * [Product / Technology](https://endocrinenews.endocrine.org/category/practice/product-technology/) * [Endocrinology Workforce](https://endocrinenews.endocrine.org/category/endocrinology-workforce/) * [Lab Notes](https://endocrinenews.endocrine.org/category/lab-notes/) * [Q&A](https://endocrinenews.endocrine.org/category/lab-notes/q-a/) * [Your Laboratory](https://endocrinenews.endocrine.org/category/your-laboratory/) * [Products and Technological Advancements in Endocrinology](https://endocrinenews.endocrine.org/category/lab-notes/products-technology/) * [Advocacy](https://endocrinenews.endocrine.org/category/advocacy/) * [Clinical](https://endocrinenews.endocrine.org/category/advocacy/clinical/) * [Research](https://endocrinenews.endocrine.org/category/advocacy/research/) * [InTouch](https://endocrinenews.endocrine.org/intouch/) * [Member News](https://endocrinenews.endocrine.org/category/in-touch/member-news-in-touch/) * [Society News](https://endocrinenews.endocrine.org/category/in-touch/society-news/) * [Podcast](https://www.endocrine.org/podcast) * [Current Issue Download](https://endocrinenews.endocrine.org/magazine/current-issue/) * [My Profile](https://ams.endocrine.org/eweb/) * [Log In](https://endocrinenews.endocrine.org/auth/login) * [Log Out](https://endocrinenews.endocrine.org/auth/logout) Search Search [Current Issue Download](https://endocrinenews.endocrine.org/magazine-issues/october-2026/) [Login](https://endocrinenews.endocrine.org/auth/login/?redirect=https://endocrinenews.endocrine.org/preconception-gestational-and-postpartum-care/) ![](https://endocrinenews.endocrine.org/wp-content/themes/mg-starter/assets/images/Endocrine_News_standard_logo.svg) * * * # Preconception, Gestational, and Postpartum Care The Critical Triad for Type 2 Diabetes and Pregnancy By Kelly Horvath November 11, 2026 Print this article Share this article ##### Type 2 diabetes is increasingly affecting women of childbearing age, making coordinated care before conception, throughout pregnancy, and after delivery essential. Based on her ENDO 2026 presentation, Aoife M. Egan, MBBCh, PhD, discusses individualized, patient-centered support to improve outcomes and reach those people who face the greatest barriers to care. At her Meet the Professor session at **ENDO 2026** in June, speaker Aoife M. Egan, MBBCh, PhD, an associate professor of medicine and consultant endocrinologist at the Mayo Clinic in Rochester, Minn., opened with three seemingly straightforward aims: to describe the essential components of preconception care for individuals living with type 2 diabetes, recommend the best management approach for type 2 diabetes during pregnancy, and outline best practices for postpartum care for individuals living with type 2 diabetes. The audience would quickly realize, however, that her guiding purpose was not solely academic — she is passionate about this area of endocrinology and hopes to make a difference in many ways in the lives of individuals with type 2 diabetes pursuing pregnancy. **At a Glance** • Individualized, patient-centered care before, during, and after pregnancy improves outcomes; the challenge is getting it to those who need it most. • Preconception care can involve patient counseling (e.g., on nutrition, lifestyle factors, diabetes self-management), health assessment including review of current medications, screening (e.g., for diabetes complications, infectious diseases), and planning for general health management, while care during pregnancy largely involves sustaining established goals by maintaining a healthy weight through diet and exercise, meeting glucose targets, and continuing to monitor for complications. • Postpartum care can involve additional postpartum appointments, virtual care, clear transition pathways, and a designated healthcare worker. ## **A Growing Problem** The session was timely, given that frequency of type 2 diabetes diagnosis continues to increase and, alarmingly, at ever younger ages. “We’re seeing more and more people of childbearing age being diagnosed with type 2 diabetes,” Egan says. “In younger people, it tends to be a more aggressive phenotype, and these individuals tend to progress more rapidly to diabetes-related complications unless they get interventions that help control their blood sugar and other comorbidities.” The rates of pregestational, or preexisting, diabetes mellitus (PDM) have skyrocketed in the last decade. Egan extrapolates data from the United Kingdom, which regularly audits national pregnancy outcomes. “We can see now that the prevalence of type 2 diabetes has far surpassed the prevalence of type 1 diabetes in pregnancy, especially in groups at greater risk of type 2 diabetes,” she says. By 2021, 10.9 of 1,000 births were complicated by PDM, up 27% in just five years from 2016. Why the rate of type 2 diabetes is still rising is no mystery, given the concomitant obesity pandemic and the often co-occurring lifestyle factors, including decreased physical activity and increased reliance on suboptimal nutrition, such as increased intake of highly processed foods. Average maternal age at childbirth is also creeping upward, which raises the likelihood of a chronic condition developing before pregnancy, from a simply temporal standpoint. “There may also be a transgenerational effect,” notes Egan. “Data are emerging that if a child is born to a mom who had any form of diabetes during pregnancy, that child is at greater risk of type 2 diabetes than an individual born to a mother with normal glucose levels in pregnancy. That risk will accumulate over time as long as our prevalence of diabetes in pregnancy continues to increase.” > ![](https://endocrinenews.endocrine.org/wp-content/uploads/Aoife-Egan-682x1024.jpg) > “I feel that women with any form of diabetes in pregnancy, not just type 2, should be able to have a positive experience and a positive pregnancy outcome, for both mom and baby. Apart from rare scenarios where pregnancy is not advised, the majority of women can get pregnant and have a good pregnancy outcome.” – Aoife M. Egan, MBBCh, PhD, associate professor of medicine, consultant endocrinologist, Mayo Clinic, Rochester, Minn. The terrible irony is that this problem disproportionately affects groups with least access to care, such as those with health literacy or socioeconomic status challenges or belonging to ethnic minorities. Consider that public health efforts to combat the obesity pandemic may not reach those groups “with the same vigor and penetration as they do the more affluent members of our society,” as Egan aptly put it. Related concerns apply to weight loss surgery and weight loss medications: Those who may need them most may face insurmountable cost and coverage barriers. ## **Three Practice Gaps** Amid this setting, Egan points to three yawning practice gaps. “First, most people with type 2 diabetes do not receive any form of preconception counseling or care,” she says, “which leaves them not well prepared in terms of glucose control and in turn to avoid the pregnancy complications that can occur with diabetes.” What the ideal preconception scenario might look like includes screening for pregnancy intent at every clinical visit with contraception advice if pregnancy is not desired and preconception care if it is. It also includes a supportive environment with a multidisciplinary care team comprising an endocrinologist, maternal-fetal medicine specialist, dietician, diabetes educator, and any additional specialists as the individual case warrants. The second relates primarily to medication but certainly ties into the first. While the pharmacotherapy landscape in type 2 diabetes has overall improved dramatically with the advent of GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors that help people improve glucose control, lose weight, and avoid the inconvenience of insulin with its multiple daily injections, evidence that these medications are safe in pregnancy is as yet lacking. Without preconception care, many women become pregnant while taking them, necessitating rapid decision-making about next therapeutic steps. Transitioning to a different program in early pregnancy, one that will likely include insulin (or possibly metformin in certain cases), can risk glucose destabilization as well as rebound weight regain. “We want to be able to stop the medications in a controlled setting where the individual has access to a dietitian especially, but also other potential members of the care team,” explains Egan. “So, again, it’s ideal to do that before pregnancy rather than in the midst of the first trimester, when they’re battling other pregnancy-related symptoms.” Although not unique to pregnancy or even to type 2 diabetes, the third gap nevertheless has especially detrimental consequences in this realm: fragmentation of care. “Ideally, women may work with an obstetrician or a maternal-fetal medicine consultant during pregnancy, with the goal of transitioning back to primary care, family medicine, or endocrinology,” she says. “For a lot of women, that just doesn’t happen, nor does important communication between the specialties.” Add missed appointments. Egan describes the “perfect storm” many women face that prevent them from getting postpartum follow-up: “Busy young mothers who are caring for children and running a household oftentimes don’t prioritize their own health during this important time and are additionally sometimes under pressure to return to work quickly after delivery.” ![](https://endocrinenews.endocrine.org/wp-content/uploads/DiabetesPreg-at-ENDO-1024x576.jpeg) _**Aoife Egan, MBBCh, PhD (center, rear) with her cohorts from the Mayo Clinic as they strike a pose at ENDO 2026 in Chicago. Pictured are: Barck row: Marius Stan, MD; Ricuarte Crespo Trevino, MD; Aviva Atri Schuller, DO; Egan; Ewelina Niedzialkowska, MD; Suhail Saad Omer, MD; and David Toro Tobon, MD. Front row (l to r): Rick Lindsey, MD, PhD; M. Regina Castro, MD; Shireen Chacko, MD; and Lucinda Gruber, MD.**_ Fragmentation, she explains, is a worldwide problem. Even if a nation’s health system itself is not fragmented, “people still need to be able to access it and people still need to want to access it.” Although clinicians cannot control everything that contributes to this thorny issue, they can help with the fragmentation. Egan recommends clearly documenting a postpartum diabetes plan in patients’ electronic medical records, confirming with them who will pick up their care, and communicating directly with those next providers, so they are in turn clear on the follow-up recommendations. For women at higher risk of being lost to follow-up, she suggests designated healthcare workers (e.g., at the hospital or state level) who can help them navigate the system. Virtual care has clear possibilities here as well, especially for those battling the “perfect storm.” ## **A Call to Action** The audience response was robust, and Egan fielded many questions. “People appreciated a focus on type 2 diabetes, because a lot of pregnancy talks focus on type 1 diabetes,” Egan says, and they valued the guidance on which medications to prescribe, how to follow these women over time, the up-to-date discussion of available options, and how we manage their care at Mayo Clinic. Hopefully some people got some ideas about how to restructure their practice to ensure that these women get the care they need.” In addition to these practical, actionable steps to promote longitudinal care, the Endocrine Society published “**[Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline](https://academic.oup.com/ejendo/article/193/1/G1/8196429)** ” in July 2025, that synthesizes the existing evidence on medications in particular. Egan agrees that they provide very helpful guidance for clinicians practicing in this area and consulted them for her own presentation. She has also co-authored a perspective piece on type 2 diabetes and pregnancy for The _Journal of Clinical Endocrinology & Metabolism_, due to publish soon. > “We’re seeing more and more people of childbearing age being diagnosed with type 2 diabetes. In younger people, it tends to be a more aggressive phenotype, and these individuals tend to progress more rapidly to diabetes-related complications unless they get interventions that help control their blood sugar and other comorbidities.” – Aoife M. Egan, MBBCh, PhD, associate professor of medicine, consultant endocrinologist, Mayo Clinic, Rochester, Minn. What it all comes down to for Egan is an intertwined message of encouragement to clinicians and to patients. “Although women currently giving birth with type 2 diabetes experience suboptimal pregnancy outcomes, it is very clear that individualized, patient-centered care can improve these outcomes,” she says. “I wanted to leave attendees with a challenge to try to get that care to those who need it most: in their practice, in their community, in their state, and on a national level. I think these women have been an underserved group, and the clinical situation is increasing in prevalence, so we need pre-pregnancy, pregnancy, and postpartum care that’s accessible and effective.” That powerful message surely landed as intended, but Egan’s crusade is also meant to reach the women grappling with this chronic disease, some of whom feel so discouraged by it all that they avoid pregnancy altogether. “I really do feel passionately about this,” she says. “I feel that women with any form of diabetes in pregnancy, not just type 2, should be able to have a positive experience and a positive pregnancy outcome, for both mom and baby. Apart from rare scenarios where pregnancy is not advised, the majority of women can get pregnant and have a good pregnancy outcome.” Egan’s work does more than close gaps; it fills them up with hope. _Horvath is a freelance writer based in Baltimore, Md. In the October issue, she wrote “_** _[Closing Windows of Vulnerability: EDC Exposure During Development](https://endocrinenews.endocrine.org/closing-windows-of-vulnerability-edc-exposure-during-development/)_** _” about how early-life exposure to endocrine-disrupting chemicals can affect various endocrine functions._ * * * ## TOPICS IN THIS ARTICLE: [Diabetes News and Research](https://endocrinenews.endocrine.org/category/diabetes-news-and-research/)[Reproductive Issues](https://endocrinenews.
## Related Clinical Research

- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)
- [Optimizing Basal Insulin Therapy for Type 2 Diabetes: The Role of Once-Weekly Insulins](https://medichelpline.com/clinical-feed/endocrine-news-0-advancing-basal-insulin-therapy-in-type-2-diabetes-individualizing-treatment-in.md)
- [Antidiabetic regimens and risk of cognitive disorders in type 2 diabetes: large retrospective coho](https://medichelpline.com/clinical-feed/plos-one-23-antidiabetic-medications-and-risk-of-cognitive-disorders-in-type-2-diabetes-a.md)
- [Cardiovascular safety of oral orforglipron versus insulin glargine in T2D at increased CV risk (AC](https://medichelpline.com/clinical-feed/pubmed-42815506.md) (DOI: 10.1016/S0140-6736(26)01865-9)
- [Safiglipron vs dapagliflozin in type 2 diabetes: phase 3 randomized double-blind OUTSTAND-2 results](https://medichelpline.com/clinical-feed/nature-0-oral-small-molecule-glp-1ra-safiglipron-versus-dapagliflozin-in-type-2-diabetes.md)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.